Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00866697 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase 3 study of Ovarian Cancer, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 940
- Enrollment target
- 20
- Study locations
NCT00866697 is a Phase 3 study of Ovarian Cancer that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 940 participants, above the 726-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (29% higher). The trial reports 20 study locations across 1 state.
The verdict
NCT00866697, a Phase 3 study of Ovarian Cancer, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 940 participants
- Enrollment target
- 20
- Study locations
Study Summary
This was a study to determine whether therapy with pazopanib was effective and safe in women with epithelial ovarian, fallopian tube, or primary peritoneal cancer whose cancer had not progressed on first line chemotherapy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pazopanib
Study Locations (20)
California
- Novartis Investigative Site - Anaheim
- Novartis Investigative Site - Baldwin Park
- Novartis Investigative Site - Bellflower
- Novartis Investigative Site - Duarte
- Novartis Investigative Site - Fontana
- Novartis Investigative Site - Hayward
- Novartis Investigative Site - Irvine
- Novartis Investigative Site - Long Beach
- Novartis Investigative Site - Los Angeles
- Novartis Investigative Site - Los Angeles
- Novartis Investigative Site - Los Angeles
- Novartis Investigative Site - Oakland
- Novartis Investigative Site - Ontario
- Novartis Investigative Site - Orange
- Novartis Investigative Site - Panorama City
- Novartis Investigative Site - Riverside
- Novartis Investigative Site - Roseville
- Novartis Investigative Site - Sacramento
- Novartis Investigative Site - Sacramento
- Novartis Investigative Site - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 940 participants |
| Start Date | 2009-05-26 |
| Est. Completion | 2017-08-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00866697
The ClinicalTrials.gov registry entry for NCT00866697 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 940 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 726-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (29% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00866697 reports 20 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00866697 about?
NCT00866697 is a clinical study titled "Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". This was a study to determine whether therapy with pazopanib was effective and safe in women with epithelial ovarian, fallopian tube, or primary peritoneal cancer whose cancer had not progressed on first line chemotherapy.
What is the current status of trial NCT00866697?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 940 participants. The study started on 2009-05-26. Estimated completion is 2017-08-24.
What conditions does trial NCT00866697 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT00866697?
The interventions under investigation include: Placebo (DRUG), Pazopanib (DRUG).
Who is sponsoring clinical trial NCT00866697?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00866697 being conducted?
This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RECRUITING · Phase 3
-
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
RECRUITING · Phase 3
-
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
RECRUITING · Phase 3
-
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.